Summary In this preclinical study, the potential applicability of an anti-B7-1 immunotoxin (IT) line Raji (IC50 10-11 M), R-S cell lines HDLM2, KM/H2 and L428 and also against a B7-1 -transfected epithelial cell line, A431, whose parental line lacks expression of B7-1. In clonogenic assays with Raji cells or KM/H2 cells, a 3-or 4-log kill, respectively, was observed. No cytotoxicity was found against the B7-1-epithelial and endothelial cell lines or against haematopoietic progenitor cells. In conclusion, an anti-B7-1 immunotoxin was developed that had good cytotoxicity against R-S cell lines and that may be used in the elimination of R-S cells in vivo. A concomitant elimination of activated antigen-presenting cells may avoid development of antitoxin and anti-mouse Ig responses and allow repeated administration.
Hodgkin's disease (HD) comprises a group of malignant lymphomas of mixed cell type that share clinical and pathological features. Typically, there is the presence of mononucleated Hodgkin cells and multinucleated Reed-Stemnberg cells (H/R-S) surrounded by a mixture of activated but non-malignant lymphocytes, histiocytes and eosinophils (Poppema, 1989; Haluska et al, 1994) . In HD, the constitutional 'B' symptoms such as fever, night sweats, generalized itching and weight loss, and other clinical features, such as eosinophilia, acute-phase reactants, thrombocytosis and sclerosis of HD-involved tissues, are very likely caused by an unbalanced production of cytokines by these H/R-S cells.
HD is a tumour that is highly responsive to both chemotherapy and radiotherapy (DeVita and Molloy Hubbard, 1993) . Most patients with early-stage disease can be cured by single-modality treatment. Advanced HD is generally treated with combination chemotherapy with good results. However, about 20% of patients will eventually suffer from a drug-resistant relapse of their disease. For these patients, and for patients with primary resistant HD, other treatment strategies are warranted. A promising approach is immunotherapy using monoclonal antibodies (MAbs) to deliver therapeutically active agents to the cancer site. As H/R-S cells are believed to be the malignant cells in HD, these cells seem to be the best target for such immunotherapy. The antigenic make-up of H/R-S cells include several well-expressed surface antigens: CD15, CD30, CD40, IL-2R (CD25), transferrin receptor (CD71), B7-1 (CD80) and B7-2 (CD86) Durkop et al, 1992; Falini et al, 1992a; Nozawa et al, 1993; Smith et al, 1993; Gruss et al, 1994; Munro et al, 1994; Falini et al, 1995) , to which a therapeutic agent could be targeted. The active moiety coupled to a MAb may consist of a radio isotope (radioimmunoconjugate) (Vriesendorp et al, 1991) or a protein synthesis-inactivating toxin (immunotoxin, IT) (Falini et al, 1992b) . As treatment modality for HD, immunotoxins may be preferred to radioimmunoconjugates, as the latter are less well targeted to a particular cell type, and other cells around the H/R-S cells will be damaged. Moreover, patients have often been treated with radiotherapy in an early stage of their disease, which may result in radioresistance. The efficacy of an IT depends largely on the choice of the target antigen. As ITs display their toxic action only inside the cell, efficacy of an IT depends, in addition to the level of antigen expression, on internalization and intracellular routing of the IT. Furthermore, not only reactivity of the MAb to the neoplastic cells should be considered but also reactivity to other cells and tissues, as serious problems may arise from using broadly reactive MAbs because of destruction of healthy tissues (Pai et al, 1991) .
In this study, we have evaluated whether an anti-B7-1 IT could be a possible HD treatment, taking into account efficacy and toxicity.
MATERIALS AND METHODS
Cell culture and MAbs Cells of the Burkitt lymphoma-derived B-cell line Raji and the Reed-Steinberg cell lines HDLM2, KM/H2 and L428 were cultured in RPMI-1640 supplemented with 10% heat-inactivated fetal calf serum (FCS), 2 mM L-glutamine, 100 IU ml-l penicillin and 100 j gml-' streptomycin, in humidified air with 5% carbon dioxide at 37°C. Endothelial cells were isolated from human umbilical vein (HUVECs) and cultured as described above, except that FCS was replaced with 10% heat-inactivated human AB serum. The cell lines HepG2 (hepatocyte derived), A431 (epidermoid vulva carcinoma derived) and its derivative, a B7-1-transfected and -expressing A431, were cultured in Dulbecco's modified Eagle medium supplemented as described above.
Normal bone marrow (BM) was obtained from patients undergoing cardiac surgery. Specimens were obtained with appropriate informed consent. Heparinized samples were diluted 1 + 1 with phosphate-buffered saline (PBS) , and mononuclear cells were isolated by gradient centrifugation on Ficoll-Hypaque.
Murine MAb B7-24 (IgG2a) directed against the human B7-1 antigen was obtained from Innogenetics, Ghent, Belgium (De Boer et al, 1992) . MAbs reactive with CD3, CD14, CD19, CD34, goat anti-mouse antibodies conjugated to fluorescein isothiocyanate (FITC) and phycoerythrin (PE) and streptavidin-PE were purchased from Becton Dickinson (San Jose, CA, USA). Preparation of anti-B7-1-saporin IT Anti-B7-1 IT was prepared as described previously (Vooijs et al, 1996) and consisted of B7-24 MAb conjugated to the type 1 ribosome-inactivating protein saporin. Large-scale saporin purification was performed as described previously (Barbieri et al, 1987 . Cells were stained with B7-24 followed by FITC-conjugated goat anti-mouse 1g (shaded peak). As negative control staining, an isotype-matched mouse Ig was used (clear peak)
Anti-B7-1 immunotoxin for therapy for Hodgkin's disease 1165 Ribosome inactivation activity of free and conjugated saporin was tested in a reticulocyte lysate system, as described previously (Parente et al, 1993) . The cytotoxic effect of the IT on cells was assessed by measuring their capacity to inhibit protein synthesis in a concentration-dependent way. Cells were seeded in 96-well round-bottom plates and incubated with anti-B7-1 IT or a mixture of MAb + saporin for 72 h in concentrations ranging from 103 M to 10-8 M referring to the saporin moiety. Thereafter [3H]leucine (1 gCi) was added to each well, followed by an ovemight incubation, resulting in a total incubation time in the presence of IT of 88 h. This incubation time resulted in the optimal cytotoxic effect, as determined by measuring [3H] Toxicity to haematopoietic progenitor cells (HPC) Bone marrow mononuclear cells were resuspended in RPMI1640 containing 10% AB serum, 2 mm L-glutamine, 100 IU ml-' penicillin and 100 jig ml-' streptomycin with or without 10-M anti-B7-1 IT or MAb + saporin separately. For the enumeration of colony-forming unit granulocyte-macrophage (CFU-GM) colonies, 100 units ml-' granulocyte-macrophage colony-stimulating factor (GM-CSF) and 10 units ml-1 interleukin 3 (1L-3) were added; for burst-forming unit eryftroid (BFU-E), 3 units ml-1 erythropoietin (Epo); and for colony-forming unit granulocyte-erythroid-macrophage-megakaryocyte (CFU-GEMM), 10 units ml-' IL-3 and 3 units ml-' Epo. Methylcellulose was added to a final concentration of 0.9%. Finally, the cells (2 x 105) were plated out in 3-cm Petri dishes and incubated at 37°C and 5% carbon dioxide. After 14 days, colonies of >20 cells were counted.
Clonogenic assay
A modification of the clonogenic assay according to Bast was performed (Bast et al, 1985; Haagen et al, 1995; Post et al, 1995 (Johnson and Brown, 1961) . The logarithmic (log) kill of IT can be determined by comparing the CU of treated and untreated cells.
RESULTS

Immunohistochemistry
To evaluate the potential cross-reactivity of anti-B7-1 IT, immunohistochemistry was performed with anti-B7-1 MAb on samples of normal lymphoid (lymph node, spleen, tonsil, and thymus) and Reactivity in the thymus was restricted to stromal cells, mainly in the medullary area and in the cortex. In spleen, tonsil and lymph node, most of the reactivity was found on macrophages and dendritic cells in the T-cell area and sinuses. B-cell reactivity was limited to the larger cells in the germinal centre; plasma cells were negative for B7-1. Reactivity in non-lymphoid tissues was limited to a weak staining of some stromal cells in Figure 1 , showing that both B7-1 and CD30 have a similar strong expression on H/R-S cells.
Reactivity of anti-B7-1 MAb with haematopoietic cells and cell lines B7-1 expression on mononuclear cells from peripheral blood and bone marrow and polymorphonuclear granulocytes from peripheral blood was determined by incubation of the cells with B7-24.
In peripheral blood, B7-1 expression was found on about 5% of the monocytes (CD14+), but not on B-cells (CD 19+), T-cells (CD3+) or granulocytes (data not shown).
After activation with interferon-y, about 80% of the monocytes became positive with an expression level similar to EBV-B cells (data not shown). Double fluorescence of B7-24 and anti-CD34 MAb showed no expression of B7-1 on CD34+ cells from bone marrow on three independent samples (data not shown).
Expression of B7-1 using B7-24 MAb was also determined on several cell lines. Results are shown in Figure 2 . B7-1 was expressed on cell lines Raji and R-S cell lines KM/H2 and L428 at a similar level; R-S cell line HDLM2 had a slightly lower expression. The cell lines A431 and HepG2, and HUVECs did not show expression of B7-1.
Characterization and cytotoxicity of anti-B7-1 IT
The biochemical characterization of anti-B7-1 IT is shown in Table 1 . The conjugation ratio is near the desired optimum of 1 mol of toxin per mol of MAb. Saporin activity is retained sufficiently, as determined on reticulocyte lysate and compared with free saporin.
Binding activity of the anti-B7-1 IT to the target cell was compared with the binding of the native MAb. Raji cells were stained with biotinylated B7-24 in the presence of increasing concentrations of native MAb or IT and stained with second-step streptavidin-PE. Results are shown in Figure 3 . The binding of anti-B7-1 IT was almost similar to the binding of B7-24.
The specific activity of the IT was determined by the treatment of different B7-1-expressing cell lines. Results are shown in Figure 4 .
Anti-B7-1 IT appeared cytotoxic for Raji cells and the R-S cell lines HDLM2, KM/H2 and L428. No cytotoxic effect of free saporin, MAb or the mixture of the two was seen with the concentration range used. No cytotoxicity was found on the B7-l-negative cell lines A43 1, HepG2 or HUVECs (data not shown). Bone marrow mononuclear cells (n = 3) were incubated with either culture medium (-), free MAb with free saporin (anti-B7-1 + saporin) or anti-B7-1 IT. Anti-CD71 IT, targeted to the transferrin receptor, was used as positive control. CFU-GEMM, CFU-GM and BFU-E were determined as decribed in Materials and methods. Because of the wide range of colonies found in the different samples, colony numbers are expressed as a percentage of the number of colonies found with culture medium (range of number of colonies is shown between brackets).
The specificity of the anti-B7-1 IT was proven by incubation of a B7-1-transfected A431. A431 normally lacks expression of B7-1 and is not affected by the IT, however a B7-1-expressing transfectant of A431 was effectively inhibited in its protein synthesis by anti-B7-1 IT ( Figure SA) . The cytotoxicity of anti-B7-1 IT was also inhibited by the addition of free B7-24, but not by the addition of an isotype-matched control MAb ( Figure 5B ).
Clonogenic assay
To examine whether treatment of B7-1-expressing cells with anti-B7-1 IT affects clonogenicity of these cells, and to get a more quantitative measurement, a clonogenic assay was performed with Raji cells and KM/H2 cells, which both show good clonogenic growth in vitro. With untreated cells, about 105 clonogenic units were scored with Raji cells and 106 clonogenic units with KM/H2.
As shown in Table 2 , treatment with anti-B7-1 IT resulted in a 3-log kill in the case of Raji and a more than 4-log kill in the case of KM/H2 cells, whereas incubation with anti B7-1 and saporin separately had no effect on clonogenic growth of either cell line.
Effect on haematopoietic progenitor cells
The effect of treatment on bone marrow with anti-B7-1 IT was studied by incubating bone marrow mononuclear cells with IT (10O8-M) and subsequently determining CFU-GEMM, CFU-GM and BFU-E. Only a slight inhibition of colony growth of normal BM HPC (Table 3) was seen with anti-B7-1 IT. This inhibition was not significantly different from the inhibition found with anti-B7-1 and saporin when added separately. An anti-transferrin receptor MAb-saporin IT (anti-CD71 IT) was used as positive control and resulted in the complete abrogation of haematopoietic progenitor cells.
DISCUSSION
The mouse IgG2a MAb against B7-1 (B7-24) used in this study appeared to have strong reactivity with R-S cell lines and with H/R-S cells in immunohistochemistry. B7-1 expression on H/R-S cells was more or less similar to CD30 expression, confirming previously published data (Nozawa et al, 1993; Gruss et al, 1994; Munro et al, 1994) . In addition to H/R-S cells, reactivity in normal British Joumal of Cancer (1997) 76(9) (Freeman et al, 1989; Guinan et al, 1994) . In peripheral blood, no reactivity was found with lymphocytes, granulocytes or the large majority of monocytes. Not reported before is the absolute absence of expression of B7-1 on CD34+ cells, representing the haematopoietic progenitor cells. Furthermore, in the screening of a large number of normal tissues by immunohistochemistry, no evidence was found for reactivity of anti-B7-1 MAb with endothelium, epithelium, connective tissue, muscle or neural cells.
The newly constructed B7-1 immunotoxin with saporin as toxin moiety appeared to effectively inhibit protein synthesis in the B7-1-expressing B cell line Raji and the R-S cell lines HDLM2, KM/H2 and L428, but not in B7-1-negative cell lines. Moreover, specificity was demonstrated with a B7-1-transfected epithelial cell line, whose parental line lacks B7-1. Maximum level of inhibition was reached at an IT concentration of 10-10-10-9 M. However, this inhibition seems not to be complete. This could be because of either complete inhibition of protein synthesis in a percentage of cells or because of an incomplete inhibition in all cells. To investigate in more detail and the effect of inhibition on cell growth, clonogenic cell assays were performed, which have been shown to be more sensitive and to provide a quantitative measurement of cytotoxic potency (Post et al, 1995) . In such a clonogenic cell assay with the B cell line Raji and R-S cell line KM/H2 a 3-log kill and a 4-log kill, respectively, was found with a single dose of 10-8 M B7-1 IT; a small population of cells survived. Therefore, it is more likely that protein synthesis is inhibited completely in a large percentage of cells, but that some cells are not affected under these conditions. The cytotoxic potency of this B7-1 IT shows that B7-1 can be intemalized upon binding of the MAb. In line with our data on absent expression of B7-1 on CD34+ cells from bone marrow, B7-1 IT did not affect the formation of CFU-GEMM, CFU-GM and BFU-E from HPC.
In vitro, the B7-1 IT shows an efficacy against R-S cell lines that is similar to that described for CD30 IT (Engert et al, 1990; Tazzari et al, 1992) . CD30 ITs have been further tested in a SCID mouse model (Engert et al, 1990; Pasqualucci et al, 1995) and comparison of B7-1 IT and CD30 IT in such a model with R-S cell lines would reveal any difference in efficacy in vivo. Of importance when considering in vivo use in humans may be that soluble CD30 is described in patients with advanced HD (Josimovic et al, 1989; Pizzolo et al, 1990; Gause et al, 1991) . This soluble form may intercept the IT before it reaches the tumour site and thereby negatively influence the therapeutic efficacy. Data on the presence of soluble B7-1 are still lacking. If IT is both efficacious in vitro and in vivo in the SCID mouse model, differences in toxicity will be important when choosing between these two IT. In addition, a B7-1 IT could be useful in combination with CD30 IT to eliminate variants with or without a low expression of one of the antigens.
Based on the literature, our immunohistochemistry data and data from FACS analysis, one can expect the following side-effects from systemic B7-1 IT treatment. B7-1 is constitutively expressed on lymphoid dendritic cells of mice and humans (Young et al, 1992; Vandenberghe et al, 1993; Caux et al, 1994; Larsen et al, 1994; Zhiou et al, 1995) and on activated B-cells and monocytes/macrophages, i.e. on all antigen-presenting cells (APC) (Freeman et al, 1989; Guinan et al, 1994) . These cells would, probably, all be killed by a B7-1 IT as has been shown by us for activated B-cells. It can be expected that systemic administration of B7-1 IT will result in transient elimination of activated (lymphoid) dendritic cells, as these cells will rapidly be replaced by circulating nonlymphoid dendritic cells, which have been shown not to express B7-1 (McLellan et al, 1995) , and eventually also by CD34+ HPC, which have also been found to be negative for B7-1. The same repopulation applies to activated monocytes and macrophages. Some macrophages, such as alveolar macrophages, will be spared as they seem to be B7-1 negative (Chelen et al, 1995) . It is still a matter of debate whether Langerhans cells (LC) express B7-1 (Symington et al, 1993; Vandenberghe et al, 1993) . In this study, no reactivity of Langerhans cells in situ was found. Primary responses may therefore be only slightly affected but will still be possible after treatment. Activated B-cells will be rapidly replaced by resting B-cells, and ongoing antibody production will not be affected as plasma cells lack B7-1. Another important point is that activated T-cells and cytotoxic T-lymphocytes (CTLs) are independent of B7 stimulation, hence these responses will not be affected by B7-1 IT (Azuma et al, 1992; Azuma et al, 1993) .
We postulate that transient elimination of activated APC will not seriously affect primary immune responses and the defence against micro-organisms. On the other hand, such elimination of APC may have a favourable effect, as responses to mouse antibodies (HAMA) and toxins (HATA) may be prevented. Particularly in patients with solid tumours (Hertler et al, 1988; Pai et al, 1991) and also in patients with HD (Falini et al, 1992b; Falini et al, 1995) , these responses often occur after 2-3 weeks, precluding repeated administration of antibodies. If B7-1 IT really prevents HAMA and HATA responses without affecting ongoing immune responses, a B7-1 IT may be an appropriate adjunct to any MAb or IT treatment.
We conclude that further exploration of the efficacy and toxicity of B7-1 IT in comparison to CD30 IT for the treatment of HD seems to be warranted.
